A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

Rationale For patients with cystic fibrosis (CF), the use of inhaled antibiotics has become standard of care to suppress chronic Pseudomonas airways infection. There are limited antibiotic options formulated and approved for inhaled use and antibiotic efficacies attenuate over time, making additi...

Full description

Bibliographic Details
Main Authors: Flume, Patrick, VanDevanter, Donald R., Morgan, E.E., Dudley, Michael N., Loutit, Jeffery S., Bell, Scott C., Kerem, Eitan, Fischer, R., Smyth, Alan R., Aaron, Shawn D., Conrad, Douglas, Geller, David E., Elborn, J. Stuart
Format: Article
Published: Elsevier 2016
Subjects:
Cystic fibrosis; Antibiotics; Pseudomonas; Aerosol; Fluoroquinolone
Online Access:https://eprints.nottingham.ac.uk/37661/

Similar Items

Similar Items